Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Studie zu Patritumab Deruxtecan mit anderen Antikrebsmitteln bei Teilnehmerinnen mit HER2-positivem Brustkrebs, der sich ausgebreitet hat und nicht chirurgisch entfernt werden kann (MK-1022-009)

12. November 2026 aktualisiert von: Merck Sharp & Dohme LLC

HERTHENA-Breast-01: Eine multizentrische, offene Dosisfindungsstudie der Phase 1b/2 zur Bewertung der Sicherheit und Antitumoraktivität von Patritumab Deruxtecan bei Teilnehmerinnen mit HER2-positivem inoperablem lokal fortgeschrittenem Brustkrebs oder metastasiertem Brustkrebs

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn:

  • About the safety and how well people tolerate of patritumab deruxtecan
  • How many people have the cancer respond (get smaller or go away) to treatment

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

The following countries will be participating in the trial: Canada, United Kingdom, Israel, Japan, South Korea, and USA.

Studientyp

Interventionell

Einschreibung (Geschätzt)

181

Phase

  • Phase 2
  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Haifa, Israel, 3109601
        • Rekrutierung
        • Rambam Health Care Campus ( Site 0011)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 04-7776234
      • Petah Tikva, Israel, 4941492
        • Rekrutierung
        • Rabin Medical Center ( Site 0012)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +972-505533121
      • Ramat Gan, Israel, 5265601
        • Rekrutierung
        • Sheba Medical Center ( Site 0010)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 03-5304498
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 467-8602
        • Rekrutierung
        • Nagoya City University Hospital ( Site 0020)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +81-52-851-5511
    • Ontario
      • Kingston, Ontario, Kanada, K7L 2V7
        • Rekrutierung
        • Kingston General Hospital ( Site 0061)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 6135336541
      • Toronto, Ontario, Kanada, M5G 2M9
        • Rekrutierung
        • Princess Margaret Cancer Centre ( Site 0001)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 416-946-4501
    • Quebec
      • Montreal, Quebec, Kanada, H3T 1E2
        • Rekrutierung
        • Jewish General Hospital ( Site 0003)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 514-340-8222
      • Montreal, Quebec, Kanada, H2X 3E4
        • Rekrutierung
        • Centre Hospitalier de l'Université de Montréal ( Site 0004)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: (514)890-8000 x20737
      • Seoul, Südkorea, 03080
        • Rekrutierung
        • Seoul National University Hospital ( Site 0030)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 82-2-2072-0850
      • Seoul, Südkorea, 05505
        • Rekrutierung
        • Asan Medical Center ( Site 0031)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +82-2-1688-7575
    • Colorado
      • Aurora, Colorado, Vereinigte Staaten, 80045
        • Rekrutierung
        • University of Colorado Anschutz Medical Campus ( Site 0057)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 720-848-1030
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02215
        • Rekrutierung
        • Dana-Farber Cancer Institute ( Site 0050)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 877-338-7425
    • New Jersey
      • New Brunswick, New Jersey, Vereinigte Staaten, 08901
        • Rekrutierung
        • Rutgers Cancer Institute of New Jersey ( Site 0052)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 732-235-2465
    • South Carolina
      • Greenville, South Carolina, Vereinigte Staaten, 29605
        • Rekrutierung
        • Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 864-455-3600
    • Virginia
      • Fairfax, Virginia, Vereinigte Staaten, 22031
        • Rekrutierung
        • Inova Schar Cancer Institute ( Site 0051)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 571-472-4724
    • Camden
      • London, Camden, Vereinigtes Königreich, NW1 2PG
        • Rekrutierung
        • University College London Hospital ( Site 0041)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +442034472930
    • Glasgow City
      • Glasgow, Glasgow City, Vereinigtes Königreich, G12 0YN
        • Rekrutierung
        • The Beatson West of Scotland Cancer Centre ( Site 0043)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +441413017000
    • London, City of
      • London, London, City of, Vereinigtes Königreich, EC1A 7BE
        • Rekrutierung
        • St Bartholomew s Hospital ( Site 0040)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: +442073777000

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
  • Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
  • Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation
  • Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention

Part 1 Arm 1:

  • Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
  • Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment

Part 1 Arm 2:

-Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting

Part 1 Arm 3:

-Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.

Part 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Uncontrolled or significant cardiovascular disease
  • Has any history of (noninfectious) interstitial lung disease (ILD)/ pneumonitis irrespective of steroid use or has current ILD or suspected ILD
  • Has clinically severe respiratory compromise
  • Has any history of or evidence of any current leptomeningeal disease
  • Has clinically significant corneal disease
  • Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
  • HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Part 1: Evidence of spinal cord compression or brain metastases
  • Part 2: Evidence of spinal cord compression or brain/CNS metastases.
  • Has an active infection requiring systemic therapy
  • Concurrent active HBV and HCV infection
  • Has had major surgical procedure (excluding placement of vascular access) less than 28 days

Part1: Arm 3 ONLY

- Has received prior treatment with tucatinib, lapatinib, or neratinib, or any investigational HER2-targeted tyrosine kinase inhibitors in the locally advanced or metastatic setting

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Part 1: Patritumab deruxtecan plus trastuzumab

Participants receive patritumab deruxtecan intravenous (IV) infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Andere Namen:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Andere Namen:
  • Herceptin®

Trastuzumab biosimilar administered via IV infusion

Andere Namen:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®
Experimental: Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab

Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Andere Namen:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Andere Namen:
  • Herceptin®

Trastuzumab biosimilar administered via IV infusion

Andere Namen:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®

Pertuzumab administered via IV infusion

Experimental: Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib

Participants receive patritumab deruxtecan IV infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks), and tucatinib is administered orally twice daily for each 21-day cycle, until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Andere Namen:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Andere Namen:
  • Herceptin®

Trastuzumab biosimilar administered via IV infusion

Andere Namen:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®

Tucatinib administered as oral tablets

Experimental: Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab

Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Andere Namen:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Andere Namen:
  • Herceptin®

Trastuzumab biosimilar administered via IV infusion

Andere Namen:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®

Pertuzumab administered via IV infusion

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
Zeitfenster: Up to 21 days

DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. The number of participants who experience a DLT will be presented.

Up to 21 days
Part 1: Number of Participants with One or More Adverse Events (AEs)
Zeitfenster: Up to approximately 36 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

Up to approximately 36 months
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Zeitfenster: Up to approximately 12 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented.

Up to approximately 12 months
Part 2: Objective Response Rate (ORR)
Zeitfenster: Up to approximately 36 months

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR)will be presented.

Up to approximately 36 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)
Zeitfenster: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan ADC.

At designated time points (up to ~13 months)
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADC
Zeitfenster: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan ADC.

At designated time points (up to ~13 months)
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADC
Zeitfenster: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan ADC.

At designated time points (up to ~13 months)
Part 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)
Zeitfenster: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Cmax of total patritumab deruxtecan ADA.

At designated time points (up to ~13 months)
Part 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADA
Zeitfenster: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Ctrough of total patritumab deruxtecan ADA.

At designated time points (up to ~13 months)
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADA
Zeitfenster: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the AUC of total patritumab deruxtecan ADA.

At designated time points (up to ~13 months)
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free Payload
Zeitfenster: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan free payload.

At designated time points (up to ~13 months)
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free Payload
Zeitfenster: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan free payload.

At designated time points (up to ~13 months)
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free Payload
Zeitfenster: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan free payload.

At designated time points (up to ~13 months)
Part 2: Duration of Response (DOR)
Zeitfenster: Up to approximately 36 months

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is alsoc onsidered PD. DOR as assessed by BICR will be presented.

Up to approximately 36 months
Part 2: Progression Free Survival (PFS)
Zeitfenster: Up to approximately 36 months

PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD)or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

Up to approximately 36 months
Part 2: Number of Participants with One or More AEs
Zeitfenster: Up to approximately 36 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

Up to approximately 36 months
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Zeitfenster: Up to approximately 12 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

Up to approximately 12 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Studienleiter: Medical Director, Merck Sharp & Dohme LLC

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

26. Februar 2025

Primärer Abschluss (Geschätzt)

2. August 2032

Studienabschluss (Geschätzt)

2. August 2032

Studienanmeldedaten

Zuerst eingereicht

11. November 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. November 2024

Zuerst gepostet (Tatsächlich)

13. November 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 1022-009
  • MK-1022-009 (Andere Kennung: MSD)
  • jRCT2041250022 (Registrierungskennung: Japan Registry of Clinical Trials (jRCT))
  • 2026-528266-19 (Registrierungskennung: EU CT)
  • U1111-1346-4321 (Registrierungskennung: UTN)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .